The Food and Drug Administration (FDA) has approved a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).

The FDA has approved Tyzavan, a novel ready-to-infuse, room temperature stable formulation of vancomycin, for the treatment of various bacterial infections.